Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

Resistance to the Ableson protein tyrosine (Abl) kinase inhibitor imatinib mesylate has become a critical issue for patients in advanced phases of chronic myelogenous leukemia. Imatinib-resistant tumor cells develop, in part, as a result of point mutations within the Abl kinase domain. As protein ki...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Tseng, Ping-Hui, Lin, Ho-Pi, Zhu, Jiuxiang, Chen, Kuen-Feng, Hade, Erinn M., Young, Donn C., Byrd, John C., Grever, Michael, Johnson, Kara, Druker, Brian J., Chen, Ching-Shih
التنسيق: Artigo
اللغة:Inglês
منشور في: © 2005 by The American Society of Hematology 2005
الموضوعات:
Neoplasia
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895085/
https://ncbi.nlm.nih.gov/pubmed/15665113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2004-07-2967
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة